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To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of the dual epidermal growth factor
receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992. An escalating schedule of once-daily (OD) BIBW 2992 for 14
days followed by 14 days off medication was explored. Thirty-eight patients were enrolled. Dose levels were 10, 20, 30, 45, 70, 85,
and 100mg. At 100mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhoea despite
treatment with loperamide) occurred in two patients. In the next-lower dose of 70mg, DLT (grade 3 fatigue and ALAT elevation)
occurred in one of six patients. An intermediate dose level of 85mg was studied. Here DLT occurred in two patients (grade 3
diarrhoea despite treatment and grade 2 diarrhoea lasting more than 7 days despite treatment). An additional 12 patients were
treated at 70mg. BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose
proportionality. Pharmacodynamics analysis in skin biopsies did not show significant changes in EGFR-associated biomarkers.
However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was observed. No partial or complete
responses were observed, stable disease lasting more than four cycles was seen in seven patients. The recommended dose for
studies with BIBW 2992 for 14 days followed by 14 days off medication is 70mg OD.
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Increased expression of epidermal growth factor receptors
(EGFR) is frequently found in epithelial tumours. EGFR and
HER2 play a role in carcinogenesis, and alterations in these
receptors are associated with poor outcome (Hynes and Lane,
2005). As HER2 overexpression is found to potentiate
EGFR signalling, dual inhibition of these two receptors is
considered to be of great potential clinical interest. A number of
reversible and irreversible tyrosine kinase inhibitors have been
explored in clinical trials, including the reversible dual inhibitor
lapatinib, which has recently gained approval in the USA for
patients with HER2-Neu overexpressing metastatic breast cancer
progressing after trastuzumab (Baselga et al, 2002; Geyer et al,
2006).
BIBW 2992 (Figure 1) is an irreversible dual inhibitor of EGFR
and HER2 tyrosine kinase. The inhibitory concentration (IC)50 is
0.5nM for EGFR kinase and 14nM for HER2 kinase. Related kinases
from vascular endothelial growth factor 2, C-SRC and Lck are not
inhibited at concentrations 100- to 1000-fold higher. BIBW 2992
inhibits EGF-induced EGFR phosphorylation and cellular proli-
feration in cell lines such as EGFR-overexpressing and HER2-
expressing cell lines A431, NIH-3T3-HER2, NCI-N87 and BT-474
(Boehringer-Ingelheim, data on file). Oral BIBW 2992 induced
tumour regression in mice carrying EGFR-overexpressing and
HER2-expressing A431 xenografts, in mice carrying EGFR-over-
expressing and HER2-expressing MDA-MB-453 xenografts, and
in NCI-N87 gastric and SKOV-3 ovarian models at plasma
concentrations of 80–280nM (Boehringer-Ingelheim, data on file).
Toxicity occurred in skin and kidneys in rats and the gastro-
intestinal tract in rats and minipigs.
Objectives of this study were (1) to determine maximum
tolerated dose (MTD) and dose-limiting toxicity (DLT) when
administered once-daily (OD) for 14 days followed by 14 days off
treatment, (2) to characterise safety including acute and chronic
adverse events (AE), (3) to characterise single- and multiple-dose
pharmacokinetics (PK), (4) to analyse biomarkers in skin biopsies
and (5) to assess antitumour activity.
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sPATIENTS AND METHODS
Eligibility criteria
Patients with histologically or cytologically confirmed solid
tumours historically known to express EGFR and/or HER2, for
whom no proven therapy exists or who are not amenable to
established treatments were eligible. Additional eligibility criteria
were as follows: age X18 years; Eastern Cooperative Oncology
Group (ECOG) performance status p2; life expectancy X3
months; adequate bone marrow (absolute neutrophil count
X1.5 10
9l
 1, platelet count X100 10
9l
 1), hepatic (bilirubin
p26mmoll
 1, serum alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) o3 times upper limit of normal
(ULN) or o5 times ULN in case of liver metastases) and renal
(creatinine p132mmoll
 1) function; no chemotherapy, immuno-
therapy, radiotherapy, or hormonal therapy within 28 days
excluding LHRH agonists or hormones taken for breast cancer.
A normal left ventricular ejection fraction (LVEF) based on
echocardiography or MUGA scan was required. Specific exclusion
criteria included impairment of gastrointestinal function interfering
with drug absorption or chronic diarrhoea.
Study design
BIBW 2992 was supplied by Boehringer-Ingelheim Pharma GmbH,
Biberach, Germany as tablets of 5, 20, or 100mg. Tablets were
taken 1h before breakfast. A cycle was defined as 14 days on
treatment followed by 14 days off medication. At days of
pharmacokinetic evaluation, BIBW 2992 was taken 1h before
breakfast. The starting dose corresponded with one-fifth of the
toxic dose low in rats, the most sensitive species. The dose for
successive cohorts was doubled until observation of drug-related
AE grade X2 according to common toxicity criteria v3.0 in one or
more patients in the first cycle. Thereafter escalation steps were
p50%. Should DLT be observed in one out of six patients and
dose escalation continued, escalation steps were p35%. Initially,
three patients were treated per dose level. If one patient
experienced drug-related DLT, three additional patients were
treated. When no further patient experienced DLT, the dose was
escalated. When X2/6 patients experienced DLT, three additional
patients were treated 1 dose tier below unless six had already been
treated there.
Maximum tolerated dose was defined as the highest dose with
p1/6 patients experiencing DLT during cycle 1. Dose-limiting
toxicity was defined as grade 3 or 4 nonhaematological toxicity
except untreated nausea, vomiting, or diarrhoea; grade 4
haematological toxicity; grade 3 diarrhoea, nausea, or vomiting
despite supportive care; need for loperamide for X7 days to treat
or prevent grade X2 diarrhoea; need for continuous administra-
tion of 5HT-3 antagonists or dexamethasone to treat or prevent
grade X2 nausea or vomiting; occurrence of grade X2 cardiac left
ventricular function or renal toxicity. In the absence of DLT or
disease progression, patients received six cycles and were
allowed to continue in an extension protocol. Intrapatient
dose escalation was not allowed. The study was approved by local
Ethics Committees, and all patients provided written informed
consent.
Pretreatment and follow-up studies
Prior to therapy, medical history taking and physical examination
were performed. A complete blood cell count (CBC), white blood
cell (WBC) differential and serum biochemistry were performed, as
were urinalysis, electrocardiogram, MUGA scanning and, chest
X-ray. Weekly evaluations during cycles 1 and 2 and every other
week thereafter included physical examination, AE assessment,
CBC, WBC differential and serum chemistry including renal
function. Tumour measurements and MUGA scanning were
performed every other cycle. Response was assessed using RECIST
(Therasse et al, 2000).
Pharmacokinetic sampling and data analysis
Blood samples (5ml) were collected prior to dosing and 0.5, 1, 2, 3,
4, 5, 7, 9, and 24h after drug administration on day 1 and 0.5, 1, 2,
3, 4, 5, 7, 9, 24, 48, and 72h after drug administration on day 14 of
cycle 1. Trough PK samples were taken before drug administration
on day 8 of every cycle, whereas in every subsequent cycle, a
sample was taken 24h following day 14 dose. Samples were
collected in pre-cooled EDTA-Vacutainer
s tubes and centrifuged
immediately. Plasma samples were stored at  201C. Plasma
concentrations of BIBW 2992 were analysed by validated high-
performance liquid chromatography tandem mass spectrometry
methods at Boehringer Ingelheim Pharma GmbH & Co. KG,
Germany. The calibration curves for BIBW 2992 covered a range of
0.500–250ngml
 1 plasma in undiluted samples.
Noncompartmental analysis was conducted using WinNonlin
s
(version 4.1, Pharsight, Mountainview, CA, USA). Standard
noncompartmental methods were used to calculate area under
the plasma concentration versus time curve (AUC0 24,ss), peak
plasma concentration (Cmax,ss), apparent total body clearance
(CL/Fss), apparent volume of distribution (Vz/Fss), and terminal
half-life (t1/2,ss). Accumulation ratio of Cmax and AUC of days 1 and
14 were calculated (RA, Cmax, and RA,AUC). Time to peak plasma
concentration (tmax,ss) was reported as median values.
Pharmacodynamic determinations
Punch biopsies were taken from unaffected forearm skin before
BIBW 2992 administration and at day 14 of cycle 1. Biopsies were
fixed in 10% formalin at room temperature (RT) and embedded in
paraffin. Tissue sections (4mm) were mounted on silan adhesive
‘Star Frost’ glass slides (Knittel Glaser, Braunschweig, Germany),
dried overnight at 561C, deparaffinised with xylene, and rehy-
drated. Expression of (1) Ki-67, (2) p27
KIP1 (kinase inhibitory
protein 1; KIP1), (3) EGFR, (4) phosphorylated mitogen-activated
protein kinase (pMAPK), and (5) phosphorylated Akt (pAkt) was
examined (Toyoshima and Hunter, 1994; Scholzen and Gerdes,
2000). Antibodies used were monoclonal mouse antihuman Ki-67
antigen (DakoCytomation, Glostrup, Denmark); monoclonal
mouse antihuman p27 protein (Novacastra, Newcastle, UK);
phospho-p44/42 Map kinase (Thr202/Tyr204) rabbit polyclonal
antibody (Cell Signalling Technology, Beverly, MA, USA);
phospho-Akt (Ser473) rabbit polyclonal antibody (Cell Signalling
Technology), and monoclonal mouse anti-EGFR (clone E30;
DakoCytomation). Isotype-matched negative control antibodies
and negative control mouse IgG2a, kappa (DakoCytomation)
were used to validate specificity of Ki-67, p27
KIP1, and EGFR
staining. Blocking peptides from SignalStain phospho-p44/42
(Thr 202/Tyr204) IHC detection kit (Cell Signalling Technology)
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Figure 1 Chemical structure of BIBW 2992.
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sand phospho-Akt (Ser473) blocking peptide (Cell Signalling
Technology) were included to validate pMAPK and pAkt.
Antibodies were diluted in antibody diluent (DakoCytomation)
and all antigens but EGFR required heat-mediated (pressure
cooker) antigen retrieval in sodium citrate (10mM; pH 6.0). To
unmask EGFR antigen, slides were incubated 3min at RT in
proteinase K solution. Endogenous peroxidase activity was blocked
for 5min at RT with peroxidase block and nonspecific cross-
reactivity was blocked by incubation in 1% bovine serum albumin
for 30min at RT. Slides were incubated in diluted primary
antibody and antigen detection by a two-step staining procedure
using DAKO EnVisionþ Polymer Detection System. Visualisation
was achieved by incubation at RT for 3–5min in 3,30-diamino-
benzidine chromogen-buffered substrate solution (DakoCytoma-
tion). Slides were counterstained with haematoxylin.
Ki-67- and p27
KIP1-positive keratinocytes were scored by
counting X1000 cells. The number of pMAPK-, pAkt-, and
EGFR-positive epidermal keratinocytes and staining intensity were
estimated using the Allred scoring system (Toyoshima and Hunter,
1994). The proportion of positive cells was scored on a 0–5 scale
and intensity on a 0–3 scale. Scoring of positive cells is based on
epidermal keratinocytes.
Statistical methods
Paired Student’s t-tests were employed to calculate P-value for
comparison of means and to define any statistically significant
changes in biomarker levels. Correlations among initial biomarker
levels were assessed by calculating Spearman’s rank correlation
coefficients.
RESULTS
Thirty-eight patients (Table 1) received 114 cycles of BIBW 2992.
Sequentially, dose levels studied were 10mg (n¼3), 20mg (n¼3),
30mg (n¼3), 45mg (n¼3), 70mg (n¼18), 100mg (n¼2), and
85mg (n¼6). Number of patients and cycles administered as a
function of schedule and dose are listed in Table 2.
Safety
Mild gastrointestinal AE, mainly diarrhoea and also nausea and
vomiting, were observed in 35 patients at all dose levels. Diarrhoea
was manageable with loperamide and usually was self-limiting,
requiring no medication in the 14 drug-free days. Nausea and
vomiting were mild and never required specific treatment.
One patient (dose level, 70mg) experienced reversible grade
2 stomatitis in cycle 1 and refused additional treatment.
Dose-dependent cutaneous AE manifested as dry skin, follicu-
litis, or skin rash and was frequently observed at all dose levels.
Skin rash was located on face and trunk. In nine patients,
minocycline 100mg OD during the 14 treatment days alleviated
or prevented symptoms. Skin toxicity was self-limiting and
disappeared during the 14 drug-free days.
Other AE included mild fatigue in 24 patients and self-limiting
epistaxis without changes in coagulation parameters in 20 patients.
ALT, AST, alkaline phosphatase, and bilirubin elevations were seen
at all dose levels. Grade 3 ALT (n¼2), AST (n¼1), and alkaline
phosphatase (n¼1) were observed in the 70mg group. Grade 2
ALT was observed in three patients and four patients had grade
2 AST. Grade 2 alkaline phosphatase was seen in five and grade 2
bilirubin in two patients. Consistently, elevations of liver enzymes
and bilirubin were related to the 14-day dosing schedule, with
levels decreasing after drug discontinuation.
Haematological AE consisted of grade 1 anemia in 6 and grade 1
thrombocytopaenia in two patients.
Two patients showed LVEF reduction. In one patient at 10mg,
LVEF decreased from 76 to 56% after cycle 2 and to 35% after cycle
4 (grade 3). MUGA scan after cycle 4 was performed in another
hospital. Two months after discontinuation of BIBW 2992, repeat
assessment at the original hospital showed an LVEF of 54%.
A transient decrease, despite normal ECGs and absence of clinical
signs of heart failure, cannot be excluded. Left ventricular ejection
fraction in a patient at 70mg decreased from 56 to 40% after
cycle 2 without signs of heart failure and with normal ECGs. No
follow-up is available on this patient.
Dose-limiting toxicity
At 70mg, one DLT was observed in cycle 1, consisting of grade 3
ALT and fatigue.
At 100mg, DLTs consisting of grade 3 skin rash (n¼1)
(Figure 2) and grade 3 diarrhoea despite loperamide (n¼1) were
observed in two patients. At 85mg, DLTs were seen in two patients
(grade 3 diarrhoea (n¼1) and grade 2 diarrhoea lasting X7 days
Table 1 Patient characteristics
Total 38
Male/female 19/19
Median age, years 58
Range, years 18–81
Prior chemotherapy
None 7
1–2 prior regimens 20
X3 prior regimens 11
Prior radiotherapy
No 23
Yes 15
Prior hormonal therapy
No 36
Yes 2
Tumour type
Colorectal carcinoma 10
Oesophageal carcinoma 5
Renal cell carcinoma 3
Nonsmall cell lung cancer 3
ACUP 3
Pancreatic carcinoma 2
Miscellaneous 12
Table 2 Dose escalation scheme, treatment duration
Dose level
(mg)
No. of
patients
Total no.
of cycles
No. of patients with
DLT in cycle 1
10 3 7 —
20 3 10 —
30 3 6 —
45 3 14
a —
70 18 48
b 3
85 6 16
c 2
100 2 7
d 1
Abbreviation: DLT¼dose-limiting toxicity. Administration scheme: BIBW 2992 once-
daily 2 weeks every 4 weeks.
aOne patient with a parotic gland tumour received
three additional cycles in the extension study.
bOne patient with a gallbladder
carcinoma received one additional cycle in the extension study.
cTwo patients
received one and five cycles respectively at 70mg following the onset of DLT in the
first treatment cycle.
dOne patient received only one cycle that was complicated by
DLT, one patient received cycles 3 and 4 at 85mg due to DLT in the second cycle at
100mg, and subsequently received cycles 5 and 6, as well as two additional cycles in
the extension study at 70mg.
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sdespite loperamide (n¼1)). Maximum tolerated dose was defined
at 70mg. At this dose, an additional 12 patients were studied of
which two experienced DLT, consisting of grade 3 diarrhoea
despite loperamide. Alltogether, at the recommended dose of
70mg, 3 out of 18 patients experienced DLT.
Pharmacokinetics
Plasma concentration versus time curves of 70mg BIBW 2992 on
days 1 (single dose) and 14 (steady state) are shown in Figure 3.
BIBW 2992 exhibited at least biexponential disposition kinetics.
Similar disposition kinetics were observed for 10–100mg on days
1 and 14.
Pharmacokinetic parameters of BIBW 2992 at steady state are
displayed in Table 3; tmax,ss was 1–4h postdose. Geometric mean
(gMean) Cmax,ss and exposure (AUC0 24,ss) increased over the
tested dose range. There was no indication of a ‘nondose linear’
pharmacokinetic behaviour of BIBW 2992 with moderate-to-high
inter-patient variability across the dose groups. Geometric
mean t1/2,ss ranged between 28 and 43h. An apparent high
total body clearance (CL/Fss) was determined, with gMean values
383–1390mlmin
 1. BIBW 2992 exhibited high gMean Vz/Fss
which might indicate extensive tissue distribution. Geometric
mean values for Vz/Fss were 1250–4760l. The apparent values
obtained for total body clearance and volume of distribution
should be treated with caution as the absolute bioavailability (F)o f
BIBW 2992 in humans is unknown. Steady state was reached at
latest after 8 days of OD dosing. Geometric mean RA, Cmax was
1.76–2.74, and RA,AUC was 2.42–3.82.
Pharmacodynamics
In 36 paired skin biopsies, no consistent changes in EGFR-
associated biomarkers (p27
KIP1, EGFR, pMAPK, or pAkt) were
detected. However, a marked reduction in epidermal keratinocytes
proliferation index was observed (Figure 4A–E) with the
percentage Ki-67-positive cells (means±s.d.) decreasing from
14.0±4.5 to 7.9±4.5% (Po0.0001). Only pMAPK expression
and pAkt correlated (Pearson’s r¼0.356; P¼0.045). Exploratory
analyses found no relationship between pharmacodynamics
markers and PK parameters.
Antitumour activity
No partial or complete responses were observed. Eight patients, all
treated at doses of X45mg, had minor tumour regressions. Stable
disease lasting X4 cycles was seen in seven patients with various
tumour types, amongst which colorectal and nonsmall cell lung
cancer. The median number of cycles in these patients was 6 (range
5–9). There was no relationship between occurrence of stable
disease lasting for X4 cycles and dose.
DISCUSSION
This first-in-human study evaluated feasibility of oral administra-
tion of BIBW 2992 for 14 days followed by 14 days off treatment.
Observed AE consisted of cutaneous toxicity, which was dose-
limiting in individual patients, and a recognisable pattern of
gastrointestinal AE, mainly consisting of diarrhoea, which was also
dose-limiting. On the basis of these observations, the recom-
mended phase 2 dose in this 14-day on, 14-day off schedule is
70mg OD. Safety data obtained through observation of 12
additional patients treated at this dose confirmed the correctness
of this conclusion.
In studies with EGFR tyrosine kinase inhibitors, cutaneous
toxicity and diarrhoea are prominent side effects (Hidalgo et al,
2001; Baselga et al, 2002; Dittrich et al, 2002; Ranson et al, 2002;
Hoekstra et al, 2005). Although these AE seem to have a common
underlying mechanism, the exact pathogenesis is unknown. In this
study rash, acne and dry skin showed an overall incidence of 95%.
There was no clear relationship between dose of BIBW 2992 and
frequency and/or type of skin event.
In this study, gastrointestinal AE showed a 92% incidence. These
AE also occurred at all doses and consisted of diarrhoea,
stomatitis, nausea, and vomiting. The incidence of stomatitis and
epistaxis appeared to be dose-related. The single most frequently
reported AE was diarrhoea, with an 84% incidence. In the first
cycle, a relation between incidence of diarrhoea and stomatitis was
observed. In addition, a relation between incidence of diarrhoea
and BIBW 2992 dose was observed in the first cycle, and analysing
all cycles, almost all patients developed episodes of diarrhoea.
Except for three patients at the lower dose levels, diarrhoea
started within 7 days. The onset of skin events was later than
that of diarrhoea. It is known that the epithelium of the
gastrointestinal tract contains EGFRs important for maintaining
integrity of the mucosa and for mucosal repair. Inhibiting EGFRs
could result in mucosal damage resulting in diarrhoea and/or
mucositis (Playford et al, 1996). Other AE observed in this study
were mild. Occurrences of asymptomatic increased liver enzymes
Figure 2 Grade 3 facial skin rash with ulceration and desquamation
(BIBW 2992 100mg OD).
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Figure 3 Individual (n¼18/15) and gMean drug plasma concentration–
time profiles of BIBW 2992 BS after multiple oral administration of 70mg
BIBW 2992 once-daily for 14 days to patients in treatment cycle 1 (linear
scale).
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sand bilirubin were not clearly associated with liver metastases.
Fluctuations followed the 14-day pattern of drug dosing and were
quickly reversible after drug discontinuation. Hepatotoxicity,
almost always reversible, is known to occur with another observed
AEGFR and HER2 tyrosine kinase inhibitors (Geyer et al, 2006;
Munster et al, 2007). In view of cardiac effects of trastuzumab, a
decrease in cardiac function was considered to be a potential side
effect of BIBW 2992. A change in LVEF was found in two patients
in the absence of any cardiac symptoms. Preliminary data from
X120 patients from additional trials with BIBW 2992 have not
indicated significant LVEF changes (Agus et al, 2006; Shaw et al,
2006). It remains unclear whether the observed changes were
attributable to BIBW 2992 or occurred by chance.
Three other studies with BIBW 2992 with alternative schemes
have been performed as part of a developmental programme
(Agus et al, 2006; Lewis et al, 2006; Shaw et al, 2006). In two
studies, a continuous dosing schedule was used, whereas a third
study explored a 3-week on, 1-week off schedule. Preliminary
results from all four studies support the concept that BIBW 2992 is
well tolerated with gastrointestinal and skin toxicity being dose
limiting in all studies. This pattern of toxicity indeed is completely
in line with toxicities observed in phase 1 studies with, for
example, both the reversible dual kinase inhibitor lapatinib and
the irreversible selective EGFR inhibitor EKB-569 (Burris et al,
2005; Ehrlichman et al, 2006). Partial tumour responses have been
observed in two patients with adenocarcinoma of the lung, with a
complex heterozygous EGFR mutation in one patient. The patient
has been on drug for X14 months (Shaw et al, 2006). Additional
studies of BIBW 2992 in nonsmall cell lung cancer are currently
considered.
The PK profile revealed oral bioavailability, moderately fast
absorption, and a t1/2 suitable for once-daily dosing. Maximum
plasma concentrations and exposure increased with dose, and
there appears to be dose linearity in the PK behaviour of BIBW
2992. All PK parameters displayed moderate-to-high variability
within the expected range for orally administered EGFR tyrosine
kinase inhibitors. At 70mg, Cmax was 25- to 700-fold higher than
required to inhibit in vitro EGFR phosphorylation and cellular
proliferation.
Somewhat to our surprise, no obvious BIBW 2992-related
changes in EGFR-associated biomarkers were observed in this
study. However, BIBW 2992 reduced the proliferation index of
epidermal keratinocytes, although no clear dose–effect relation-
ship was noted. Whether this somewhat disappointing result can
be explained by methodology, or whether analysis of other signal
pathways could have demonstrated biological activity of BIBW
2992 currently remains speculative. In contrast, and as mentioned
earlier, hints of clinical activity have been observed.
Recently, lapatinib added to capecitabine in trastuzumab-
refractory metastatic breast cancer patients has demonstrated
clinical efficacy (Geyer et al, 2006). BIBW 2992 targets the same
receptors as lapatinib but in an irreversible manner. This is a
potential advantage, because receptor inhibition can only be
overcome by newly synthesised EGFR and HER2. In a xenograft
model, 424h inhibition of EGFR phosphorylation was seen with
the irreversible tyrosine kinase inhibitor EKB-569, even though the
plasma half-life of this drug was 2h (Torrance et al, 2000).
Treatment with BIBW 2992 may therefore result in a sustained
inhibition of EFGR and HER2. Furthermore, in preclinical studies
the irreversible EGFR inhibitors EKB-569, CI-1033 (a pan-ErbB
inhibitor), and HKI-272 (a dual EGFR/HER2 inhibitor) have shown
inhibition of gefitinib-resistant kinases (Carter et al, 2005; Kwak
et al, 2005). Acquired or primary resistance to gefitinib or erlotinib
Table 3 Geometric mean (and CV%) pharmacokinetic parameters of BIBW 2992 BS on day 14 after single oral administration of 10, 20, 30, 45, 70, 85,
and 100mg OD BIBW 2992 tablets (for tmax,ss median (and range) is displayed)
Day 14
BIBW 2992 dose 10mg 20mg 30mg 45mg 70mg 85mg 100mg
No. of patients n¼3 n¼3 n¼3 n¼3 n¼16 n¼4 n¼1
Cmax,ss (ngml
 1) 14.1 (72.1) 16.2 (51.9) 111 (69.7) 68.4 (31.7) 180 (34.5) 163 (53.0) 234
tmax,ss (h) 2.98 (2.00–4.00) 4.00 (4.00–4.00) 0.950 (0.517–2.07) 3.00 (2.00–4.07) 2.00 (0.500–5.00) 2.00 (2.00–2.02) 1.00
AUC0 24,ss (nghml
 1) 199 (56.9) 241 (59.4) 1310 (57.5) 840 (35.0) 2620 (36.3) 2340 (47.6) 2750
t1/2, ss (h) 35.9 (12.0) 39.7 (13.4) 37.7 (25.1) 43.4 (31.4) 39.6 (38.7) 30.8 (12.9) 28.6
CL/Fss (mlmin
 1) 839 (56.9) 1390 (59.4) 383 (57.5) 893 (35.0) 445 (36.3) 604 (47.6) 606
Vz/Fss (l) 2610 (42.8) 4760 (49.3) 1250 (64.0) 3350 (57.3) 1530 (33.5) 1610 (36.4) 1500
RA,Cmax 1.76 (34.0) 2.23 (7.62) 1.90 (23.9) 2.27 (13.7) 2.74 (111) 2.01 (65.6) 2.19
RA, AUC 2.42 (33.7) 2.61 (3.65) 2.62 (36.8) 2.45 (12.9) 3.82 (116) 2.50 (66.7) 2.86
Abbreviations: OD¼once daily.
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Figure 4 Ki-67 staining of paired skin biopsies of cancer patients treated
with BIBW 2992. Pretreatment samples (A and C) and on-therapy sample
treated with 10mgday
 1 (B) or at the MTD of 70mgday
 1.( D) Original
magnification of the photomicrographs 400 . Overall effect of BIBW
2992 treatment (all dose levels pooled) on percentage Ki-67-positive
epidermal keratinocytes (mean±s.d.) in pretreatment versus on-therapy
samples (E) and the effect of treatment for each individual patient (F).
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sin NSCLC may therefore be circumvented by irreversible tyrosine
kinase inhibitors. Thus, there are some potential advantages of
irreversible tyrosine kinase inhibitors, such as BIBW 2992, over
reversible inhibitors. However, their exact role remains to be
established in future studies.
In summary, BIBW 2992 is a novel irreversible EGFR and HER2
tyrosine kinase inhibitor. When given daily for 2 weeks every 4
weeks, it is well tolerated, with AE being rash, diarrhoea, and
transaminase elevations. These AE are reversible, and the pharmaco-
kinetic profile is predictable and compatible with OD dosing.
REFERENCES
Agus D, Terlizzi E, Stopfer P, Amelsberg A, Gordon M (2006) A phase I
dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2
receptor tyrosine kinase inhibitor, in a continuous schedule in patients
with advanced solid tumours. J Clin Oncol 24: 49s (suppl, abstract 2074)
Baselga J, Rischin D, Ranson M, Cavert H, Raymond E, Kieback D, Kaye S,
Gianni L, Harris A, Bjork T, Averbuch S, Feyereislova A, Swaisland H,
Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and
pharmacodynamic trial of ZD1839, a selective oral epidermal growth
factor receptor tyrosine kinase inhibitor, in patients with five selected
solid tumor types. J Clin Oncol 20: 4292–4302
Burris H, Hurwitz H, Dees E, Dowlati A, Blackwell K, O’Neil B, Marcom P,
Ellis M, Overmoyer B, Jones S, Harris J, Smith D, Koch K, Stead A,
Mangum S, Spector N (2005) Phase I safety, pharmacokinetics, and
clinical activity study of lapatinib (GW572016), a reversible dual inhibitor
of epidermal growth factor receptor tyrosine kinases, in heavily pretreated
patients with metastatic carcinomas. J Clin Oncol 23: 5305–5313
Carter E, Wodicka L, Shah N, Velasco A, Fabian M, Treiber D, Milanov Z,
Atteridge C, Biggs W, Edeen P, Floyd M, Ford J, Grotzfeld R, Herrgard S,
Insko D, Mehta S, Patel H, Pao W, Sawyers C, Varmus H, Zarrinkar P,
Lockhart D (2005) Inhibition of drug-resistant mutants of ABL, KIT, and
EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011–11016
Dittrich Ch, Greim G, Borner M, Weigang-Ko ¨hler K, Huisman H,
Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P (2002)
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal
growth factor receptor (EGFR) inhibitor, given in a continuous daily oral
administration. Eur J Cancer 38: 1072–1080
Ehrlichman C, Hidalgo M, Boni J, Martins P, Quinn S, Zacharchuk C,
Amorusi P, Adjei A, Rowinsky E (2006) Phase I study of EKB-569, an
irreversible inhibitor of the epidermal growth factor receptor, in patients
with advanced solid tumors. J Clin Oncol 24: 2252–2260
Geyer C, Forster J, Lindquist D, Chan S, Romieu S, Pienkowski T, Jagiello-
Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M,
Davidson N, Berger M, Oliva C, Rubin S, Stein S, Cameron D (2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
New Engl J Med 355: 2733–2743
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond L, Takimoto C,
Eckhardt SG, Tolcher A, Britten C, Denis L, Ferrante K, Von Hoff DD,
Silberman S, Rowinsky E (2001) Phase I and pharmacologic study of OSI-
774, an epidermal growth factor receptor tyrosine kinase inhibitor, in
patients with advanced solid malignancies. J Clin Oncol 19: 3267–3279
Hoekstra R, Dumez H, Eskens FALM, van der Gaast A, Planting A, de Heus
G, Sizer K, Ravera C, Vaidyanathan S, Bucana C, Fidler I, van Oosterom
A, Verweij J (2005) Phase I and pharmacologic study of PKI166, an
epidermal growth factor receptor tyrosine kinase inhibitor, in patients
with advanced solid malignancies. Clin Cancer Res 11: 6908–6915
Hynes N, Lane H (2005) ERBB receptors and cancer: the complexity of
targeted inhibitors. Nat Rev Cancer 5: 341–354
Kwak E, Sordella R, Bell D, Godin-Heymann N, Okimoto R, Brannigan B,
Harris P, Driscoll D, Fidias P, Lynch T, Rabindran S, McGinnis J,
Wissner A, Sharma S, Isselbacher K, Settleman J, Haber D (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired
resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670
Lewis N, Marshall J, Amelsberg A, Cohen R, Stopfer P, Hwang J, Malik S
(2006) A phase I dose escalation study of BIBW 2992, an irreversible dual
EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off
schedule in patients with advanced solid tumors. J Clin Oncol 24: 49s
(suppl, abstract 3091)
Munster P, Britten C, Mitta M, Gelmon K, Minton S, Moulder S, Slamon D,
Guo F, Letrent S, Denis L, Tolcher A (2007) First study of the safety,
tolerability, and pharmacokinetics of CP-724,714 in patients with
advanced malignant solid HER2-expressing tumors. Clin Cancer Res
15: 1238–1245
Playford R, Hanby A, Gschmeissner S, Peiffer L, Wright N, McGarrity T
(1996) The epidermal growth factor receptor (EGF-R) is present on the
basolateral, but not the apical, surface of enterocytes in the human
gastrointestinal tract. Gut 39: 262–266
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray P, Miller V,
Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky E
(2002) ZD1839, a selective oral epidermal growth factor receptor-tyrosine
kinase inhibitor, is well tolerated and active in patients with solid,
malignant tumors: Results of a phase I trial. J Clin Oncol 20: 2240–2250
Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the
unknown. J Cell Physiol 182: 311–322
Shaw H, Plummer R, Vidal L, Perrett R, Pilkington M, Temple G, Fong P,
Amelsberg A, Calvert H, De Bono J (2006) A phase I dose escalation
study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine
kinase inhibitor, in patients with advanced solid tumours. J Clin Oncol
24: 49s (suppl, abstract 3027)
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan R, Rubinstein L,
Verweij J, Van Glabbeke M, van Oosterom A, Christian M, Gwyther S
(2000) New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer Institute
of Canada. J Natl Cancer Inst 92: 205–216
Torrance C, Jackson P, Montgomery E, Montgomery E, Kinzler K,
Vogelstein B, Wissner A, Nunes M, Frost P, Discafani C (2000)
Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:
1024–1028
Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin-cdk
protein kinase activity, is related to p21. Cell 78: 67–74
Phase I study of EGFR tyrosine kinase inhibitor BIBW 2992
FALM Eskens et al
85
British Journal of Cancer (2008) 98(1), 80–85 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s